Dr. Usmani on CAR T Cells, Bispecific Antibodies, and ADCs in Multiple Myeloma

Video

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates (ADCs) in multiple myeloma.

BCMA-targeted CAR T cells modify the immune system by activating a patient’s own T cells to recognize BCMA, a surface marker on myeloma cells. As the T cells proliferate, they attack cells expressing BCMA. Using a more specific target for CAR T-cell therapy will yield a more favorable outcome for the patient, adds Usmani.

Bispecific monoclonal antibodies can also target BCMA. One arm of the agent targets BCMA, while the other latches to CD3 on the T cell. Then, the T cell can effectively kill the myeloma cell.

A third strategy is the use of ADCs in which a cytotoxic payload, attached to an antibody, is delivered to the cancer cell. Once the toxin has been internalized, it is released, resulting in cell death.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.